Aclaris Therapeutics Inc. (ACRS)
1.57
-0.01 (-0.63%)
At close: Mar 18, 2025, 3:59 PM
1.58
0.20%
After-hours: Mar 18, 2025, 07:11 PM EDT
-0.63% (1D)
| Bid | 1.46 |
| Market Cap | 169.97M |
| Revenue (ttm) | 26.14M |
| Net Income (ttm) | -184.38M |
| EPS (ttm) | -1.71 |
| PE Ratio (ttm) | -0.92 |
| Forward PE | -4.66 |
| Analyst | Buy |
| Ask | 2 |
| Volume | 1,946,933 |
| Avg. Volume (20D) | 863,246 |
| Open | 1.59 |
| Previous Close | 1.58 |
| Day's Range | 1.55 - 1.62 |
| 52-Week Range | 0.95 - 5.17 |
| Beta | 0.50 |
About ACRS
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 6, 2015
Employees 61
Stock Exchange NASDAQ
Ticker Symbol ACRS
Website https://www.aclaristx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for ACRS stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 566.67% from the latest price.
Stock ForecastsNext Earnings Release
Aclaris Therapeutics Inc. is scheduled to release its earnings on May 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+46.18%
Aclaris Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
4 months ago
+53.17%
Aclaris Therapeutics shares are trading higher after the company announced it entered into an exclusive license agreement with Biosion for worldwide rights to BSI-045B. The company announced an $80 million private placement.
